复方黄黛片、全反式维A酸及化疗序贯治疗缓解后急性早幼粒细胞白血病临床观察  

Clinical observation of acute promyelocytic leukemia after complete remission by sequential treatment of compound huangdai tablets,all-trans retinoic acid and chemotherapy

作　　者：陆进[1] 查庆桂[1] 苗忠[1] 周广政[1] 王骏[2] 

机构地区：[1]江苏省兴化市中医院血液科,江苏兴化225700 [2]东南大学附属中大医院血液科,江苏南京210009

出　　处：《吉林医学》2007年第17期1848-1850,共3页Jilin Medical Journal

摘　　要：目的:观察复方黄黛片、全反式维A酸(ATRA)及化疗序贯治疗缓解后急性早幼粒细胞白血病(APL)的临床疗效。方法:对缓解后25例APL患者,先予DA方案(柔红霉素、阿糖胞苷)巩固2个疗程,再用复方黄黛片、ATRA及常规剂量化疗,每月序贯治疗,持续3年。持续缓解3年以上者,根据PML/RARα融合基因调整治疗方案。结果:25例全部存活,复发率8.0%。结论:复方黄黛片、ATRA及化疗序贯治疗缓解后APL,疗效满意,副作用少。Objective To observe the clinical effect of compound huangdai tablets, all- trans retinoic acid （ATRA） and chemotherapy sequentially treating acute promyelocytic leukemia （APL） after complete remission. Method Twenty - five cases of APL after complete remission were treated with DA plan （Daunorubiein and Cytosine arabinoside） first for two duration of therapy, then compound huangdai tablets, ATRA and chemothrapy of routine dosage were sequentially administered monthly for three years. For those who had remissed continuously for three years, therapy plan was rearranged according to PMI/RARα fusion gene. Results Twenty - five cases were all alive and the relapse rate was 8.0%. Conclusion Compound huangdai tablets, ATRA and chemotherapy sequentially administered for treating APL after remission is a good therapy and has fewer side effects.

关 键 词：白血病 早幼粒细胞 急性 复方黄黛片 全反式维A酸 化学疗法 

分 类 号：R733.7[医药卫生—肿瘤]